Source link : https://www.newshealth.biz/health-news/extended-imatinib-maintenance-boosts-disease-free-survival-in-high-risk-gist/
Patients with high-risk gastrointestinal stromal tumors (GISTs) had a 60% improvement in 3-year disease-free survival (DFS) with 6 versus 3 years of maintenance imatinib, a randomized trial showed. DFS at 3 years increased from 55% with 3 years of imatinib maintenance to 87% with 6 years of maintenance therapy. Patients with an estimated 35-70% risk […]
Author : News Health
Publish date : 2024-05-10 21:40:11
Copyright for syndicated content belongs to the linked Source.
in Health